RxDoctor Payments Data

Charity Eck

Acute Care · Easton, PANPI 1255975488

Payments from drug & device makers

$2,472in general payments, 2019–2025

Across 47 payments — averaging $52.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$777
  • Novocure Inc.$347
  • AstraZeneca$253
  • Incyte Corporation$247
  • Jazz Pharmaceuticals Inc.$216
  • Beigene USA, Inc.$198
  • plus $433 from 8 others

What the payments were for

  • Food & beverage$1,75671%
  • Education$71629%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,472 in reported general payments places this provider in the 90th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,407
Medicare patients
232
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabliviCaplacizumab-Yhdp13$3,192,051
ImbruvicaIbrutinib41$453,136
RevlimidLenalidomide12$215,192
IbrancePalbociclib13$208,820
XtandiEnzalutamide14$192,345
VenclextaVenetoclax12$186,481
Lenalidomide13$162,546
PromactaEltrombopag Olamine18$152,818
EliquisApixaban108$87,838
Imatinib Mesylate20$44,068
XareltoRivaroxaban19$12,847
Dabigatran EtexilateDabigatran Etexilate Mesylate16$3,092
Hydroxyurea49$1,447
Anastrozole26$725
Oxycodone Hcl30$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiCablivi$54$3,192,05113 claims
Astellas Pharma US IncXtandi$99$192,34514 claims
Johnson & JohnsonXarelto$98$12,84719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →